Nautilus Biotechnology Sees Unusually High Options Volume (NASDAQ:NAUT)

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) saw some unusual options trading activity on Monday. Stock investors acquired 3,253 call options on the stock. This is an increase of 1,427% compared to the typical daily volume of 213 call options.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Zacks Research upgraded shares of Nautilus Biotechnology to a “hold” rating in a research note on Wednesday, September 30th. Weiss Ratings lowered shares of Nautilus Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 5th. Leerink Partners initiated coverage on shares of Nautilus Biotechnology in a report on Wednesday, September 9th. They issued an “outperform” rating and a $4.00 price target on the stock. Finally, Roth Capital started coverage on shares of Nautilus Biotechnology in a research report on Tuesday, September 29th. They set a “buy” rating and a $3.50 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Nautilus Biotechnology has a consensus rating of “Moderate Buy” and a consensus target price of $3.83.

Nautilus Biotechnology Price Performance

NAUT stock opened at $1.87 on Tuesday. Nautilus Biotechnology has a fifty-two week low of $0.82 and a fifty-two week high of $4.31. The stock has a market capitalization of $237.96 million, a price-to-earnings ratio of -4.16 and a beta of 0.73. The business’s fifty day moving average price is $1.02 and its two-hundred day moving average price is $2.01.

Nautilus Biotechnology (NASDAQ:NAUT) last announced its earnings results on Monday, July 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03. The business had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.10 million. Research analysts expect that Nautilus Biotechnology will post -0.52 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Squarepoint Ops LLC bought a new position in shares of Nautilus Biotechnology during the second quarter worth approximately $63,000. Corient Private Wealth LP boosted its stake in shares of Nautilus Biotechnology by 43.6% in the second quarter. Corient Private Wealth LP now owns 164,788 shares of the company’s stock valued at $308,000 after buying an additional 50,000 shares during the period. TD Waterhouse Canada Inc. grew its position in Nautilus Biotechnology by 1,500.0% during the second quarter. TD Waterhouse Canada Inc. now owns 16,000 shares of the company’s stock worth $29,000 after buying an additional 15,000 shares in the last quarter. AXQ Capital LP acquired a new stake in Nautilus Biotechnology during the second quarter worth approximately $64,000. Finally, Susquehanna International Group LLP increased its stake in Nautilus Biotechnology by 1,710.9% during the 2nd quarter. Susquehanna International Group LLP now owns 890,949 shares of the company’s stock worth $1,666,000 after acquiring an additional 841,749 shares during the period. Institutional investors and hedge funds own 50.71% of the company’s stock.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc is a life sciences technology company developing tools for large-scale protein analysis. Its goal is to enable more comprehensive, sensitive and efficient study of the proteome, the full set of proteins expressed by a biological system, to support research in drug discovery, disease biology and translational science.

The company’s primary offering is the Nautilus Proteome Analysis Platform, which combines a proprietary analytical instrument, consumables and software.